Loading...
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated for single-agent use in the treatment of patients with multiple myeloma who have received at least 2 prior therapies and are progressing on their most recent therapy. Clinical investigations have been comp...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2005
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1164423/ https://ncbi.nlm.nih.gov/pubmed/15929791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2867-5-18 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|